Fourth Industrial Revolution

3 ways to accelerate the biomanufacturing revolution

The biomanufacturing revolution could be worth up to $4 trillion a year

The biomanufacturing revolution could be worth up to $4 trillion a year Image: Louis Reed

Prakash Iyer
Project Fellow, Shaping the Future of Advanced Manufacturing and Value Chains, World Economic Forum Geneva
Felipe Bezamat
Head of Advanced Manufacturing Industry, World Economic Forum Geneva
Our Impact
What's the World Economic Forum doing to accelerate action on Fourth Industrial Revolution?
The Big Picture
Explore and monitor how Fourth Industrial Revolution is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Fourth Industrial Revolution

  • Advances in synthetic biology are spurring a biomanufacturing revolution.
  • It can help us address our gravest challenges, from microplastic pollution to pandemic prevention and preparedness.
  • Here are 3 areas through which we can accelerate this transformation.

Our collective ability to engineer biology together with the deployment of automation, AI and data-analytics in production processes, has advanced in leaps and bounds over the last two decades, spurring a biomanufacturing revolution. Economies of scale are enabling significant cost reductions in fundamental unit operations, which in turn have enabled a maturation of the overall biological engineering toolkit.

The perception of biology has shifted from a natural phenomenon to a technology that is fundamentally 'programmable' through genetic code, DNA – and companies in this sector have seen the cost of programming cells decline by 50% every year. This technology has driven the evolution of general 'genetic engineering' approaches into the relatively newly established field of synthetic biology, which broadly seeks to design and build new biological parts, processes and systems for a specific purpose.

A new wave of innovation in synthetic biology is now capturing the attention of different stakeholders. In 2020, global venture-capital funding and deals in biotech amounted to a record $36.6 billion, while biotech IPOs raised more than twice the amount of capital compared with 2019. It's moving beyond healthcare, too; more than half of the direct impact of new biotech applications over the next 10 to 20 years is likely to be felt in sectors such agriculture and food, consumer products and services, and materials and energy production.

Have you read?

This wave of innovation, together with an ongoing fall in costs, is opening the way to sustainable, scalable and innovative biomanufacturing solutions across value chains, enabling organizations across a diverse set of value chains. According to a recent study by Mckinsey, the economic benefits could be worth up to $4 trillion per year over the next 10-20 years.

Beyond its intrinsic economic, performance and environmental advantages, biomanufacturing is also one of the most promising areas of developing technology when it comes to solving major global crises such as microplastic pollution and pandemic prevention and preparedness. Over the next two decades, it is anticipated that biomanufacturing will unlock major advances in areas such as:

1. Bioremediation: microbes and enzymes are being developed that can metabolize wastewater contaminants and transform them into useful bioproducts.

2. Biosecurity: Localized biomanufacturing capabilities across developed and developing nations will enable rapid and effective responses to emerging pandemics.

3. Bioinnovation: The development of existing and novel ingredients and materials are enhancing value chains while offering alternatives to petrochemically derived alternatives.

Many individual and joint efforts are already being directed towards these solutions; however, there are still obstacles to fully realizing the full potential of the biomanufacturing revolution. Currently there is a need to accelerate the feedback loop between biological design and product application to ensure commercial success. In order to power the diversity of applications emerging from this field over the next 20 years, significant effort is needed to grow and develop the future bioworkforce.

Biomanufacturing is moving far beyond healthcare
Biomanufacturing is moving far beyond healthcare Image: McKinsey & Company

So how can we accelerate the biomanufacturing revolution? We suggest focusing on three main areas:

1. Workforce

We need to significantly expand the biomanufacturing workforce in order to realize the full potential of the bioeconomy and to enable local, distributed manufacturing. Here's how:

  • Establish common skill and training requirements to facilitate better recognition of foreign formal qualifications and work experience to enable better workforce mobility. The shift towards automation and digitalization in manufacturing more generally has created a common skillset across traditional manufacturing technologies that could be translated for the biomanufacturing workforce.
  • Greater investment in early STEM education, with an emphasis on critical thinking and analytical problem-solving today, can encourage tomorrow's leaders of the growing global bioeconomy

2. Scale

Increasing access to scale in both the development and deployment of biomanufacturing solutions is needed to accelerate growth of the bioeconomy. Here's how:

  • Strategic partnerships across large platform developers, application-specific technologies, and mature consumer-facing companies can accelerate biomanufacturing product development.
  • Platform developers, automation and AI are generating ever-larger data sets; these can be leveraged to support faster development and scale-up.
  • A network of manufacturing partners and technologies can be challenging to assemble, but this is key when demonstrating the first pilot or commercial batches of a given product. Innovative public-private programmes and joint investments in pre-competitive ffacilities (such as a flexible biomanufacturing co-op, for example) could enable more innovation and support product development.

3. Policy

Policy must keep up with the pace of innovation in order to facilitate impactful solutions while mitigating any potential risks. Furthermore, early regulatory missteps can delay the progress of the biomanufacturing revolution and constrain innovation, especially in more forward-looking applications. Instead, we should:

  • Identify new public-private partnerships that that support the manufacture and distribution of sustainable goods enabled by innovative biomanufacturing solutions, thus providing alternatives to petrochemically derived products.
  • Joint public-private cooperation to develop biosecurity strategies that can keep pace with innovation. As the COVID-19 pandemic has demonstrated, pathogens do not respect borders; this highlights the need to include developing nations and the Global South in the planning and execution of biosecurity initiatives.
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Space: The $1.8 Trillion Opportunity for Global Economic Growth

Bart Valkhof and Omar Adi

February 16, 2024

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum